Business, energy, technology, markets and global industry news from Business News Today

DT120 ODT

PharmaDeviceNews DT120 ODT
Representative image: Definium Therapeutics’ $805 million public offering strengthens its ability to advance DT120 ODT after positive Phase 3 depression trial results, while regulatory and commercial execution remain the next major tests.
Pharma & Biotech

DT120 delivered a Phase 3 surprise. Can Definium Therapeutics turn $805m into a launch?

Definium Therapeutics has used the strong market response to its DT120 ODT depression data to secure one of the largest recent biotechnology financings, giving the psychiatric drug developer substantial resources for additional trials, regulatory work and potential commercialisation.

Read More
Representative image: Definium Therapeutics’ DT120 ODT Phase 3 Emerge study highlights the growing focus on psychedelic psychiatry and new treatment approaches for major depressive disorder.
Pharma & Biotech

Definium Therapeutics nears pivotal MDD test as DT120 ODT faces Phase 3 scrutiny

Find out how Definium Therapeutics’ DT120 ODT Phase 3 MDD readout could reshape psychedelic psychiatry and depression drug development.

Read More
Pharma & Biotech

Is lysergide finally going mainstream? Definium Therapeutics bets on DT120 ODT clinical momentum

Can DT120 ODT transform mental health treatment? Explore Definium Therapeutics’ pivotal trials and what they mean for psychedelic psychiatry.

Read More